Artios: Defining next generation DDR medicines

We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to specifically destroy certain devastating cancers that are difficult to treat.

Slider

Artios - Targeting DDR

Many cancers alter their DDR pathways to drive genomic instability and increase mutational burden in their DNA. This causes protein changes that enable the cancer cells to evolve, adapt, and become resistant to treatment.

First-in-Class

Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class and best-in-class potential. Our cutting-edge DDR programmes have applications across a broad range of cancers.

Developed by an expert team

The Artios team has many years of experience identifying and bringing to clinic high value DDR drugs. By working with industry-leading partners and investors we aim to push the boundaries in the fight against cancer.

Targeting DDR

Taking control of the DNA Damage Response